Long-term safety of steroid-sparing immunosuppression in uveitis

Corticosteroid-sparing immunosuppression is standard for chronic noninfectious uveitis, yet its long-term safety remains a dominant clinical concern. We synthesize the contemporary evidence on long-term safety, common adverse effects that drive treatment discontinuation, and how those effects are managed across various medication classes.

The largest cohort data show no statistically significant excess in overall or cancer mortality for antimetabolites, calcineurin inhibitors, or antitumor necrosis factor agents, whereas alkylating agents remain the principal malignancy concern. Discontinuation for toxicity is modest across classes and is usually driven by reversible, organ-specific effects: most often gastrointestinal intolerance for antimetabolites, nephrotoxicity for calcineurin inhibitors, and cytopenia for alkylating agents. Long-term data led by a 7-year adalimumab extension showed no new safety signals, with infection and tuberculosis reactivation as the main risks of tumor necrosis factor blockade.

Steroid-sparing agents appear to have excellent long-term safety when the agent is matched to disease severity and patients are screened and monitored proactively. The safest agent is the one whose specific toxicity is anticipated and managed.